ARCHS4: Massive Mining of Publicly Available RNA Sequencing Data
ARCHS4:大规模挖掘公开的 RNA 测序数据
基本信息
- 批准号:10814654
- 负责人:
- 金额:$ 15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:Advanced DevelopmentAntibody-drug conjugatesAtlasesCAR T cell therapyCancerousCell LineCell secretionCell surfaceCellsChildCommunitiesDataData SetDatabasesDevelopmentDiseaseExcisionFeedbackFundingFutureGene ExpressionGenesGenotype-Tissue Expression ProjectGoalsGrantHuman BioMolecular Atlas ProgramHuman Gene MappingHuman bodyImmunotherapyIndividualMiningMolecular TargetNormal tissue morphologyOntologyOrganPatientsPhysiologyProcessProtein SecretionProteinsResearchResearch PersonnelResourcesSurfaceThe Cancer Genome AtlasTimeTissuesVisualizationWorkbioinformatics toolcell typecomputerized data processingdocument outlinesexperienceimprovedindividual patientinformation organizationknowledge integrationneoplastic cellnovelonline resourceprotein expressionrepositorysingle-cell RNA sequencingstatisticstranscriptome sequencingtumorweb server
项目摘要
Summary
This supplement project will contribute to the enhancement of the TragetRanger and GeneRanger web-based
resources. The work will include: 1) Adding HuBMAP as an additional background atlas for GeneRanger and
TargetRanger; 2) Providing the HuBMAP team with feedback about our experience with processing and utilizing
the HuBMAP data for incorporation it in GeneRanger and TargetRanger; and 3) Upgrading GeneRanger and
TargetRanger box plot visualizations to organize the information in ontological hierarchies that group together
cells into tissues, and tissues into organs. The project will be a supplement to the NCI ITCR U24CA264250 grant
that was funded to support the advanced development of the widely accessed resource ARCHS4. Data
processed from ARCHS4 is already incorporated into GeneRanger and TargetRanger but it is currently not
organized into hierarchies. In addition, TargetRanger is mainly useful for discovering novel targets for identifying
and removing cancerous cells in tumors. Hence, the incorporation of HuBMAP data as normal tissue background
will further strengthen our ability to distill useful targets for the removal of specific cells from tumors while causing
minimal damages to normal healthy cells and tissues throughout the human body. Our goal is to make HuBMAP
and ARCHS4 data more accessible to researchers while enabling comparisons with other atlasing projects. By
processing and incorporating HuBMAP datasets into GeneRanger and TargetRanger resources, we can identify
ways to improve the accessibility of HuBMAP data for others seeking to utilize it for analysis, and for adding
value to bioinformatics tools and databases. We believe that this knowledge integration effort will enhance the
utility of HuBMAP, ARCHS4, as well as GeneRanger and TargetRanger for the research community.
总结
该补充项目将有助于增强基于网络的TracetRanger和GeneRanger
资源工作将包括:1)添加HuBMAP作为GeneRanger的额外背景图谱,
TargetRanger; 2)向HuBMAP团队提供有关我们处理和利用经验的反馈
用于将其并入GeneRanger和TargetRanger的HuBMAP数据;以及3)升级GeneRanger,
TargetRanger箱形图可视化,用于在分组在一起的本体层次结构中组织信息
细胞转化为组织,组织转化为器官。该项目将是NCI ITCR U24 CA 264250赠款的补充
这是资助支持广泛访问的资源ARCHS 4的高级开发。数据
从ARCHS 4处理的数据已经整合到GeneRanger和TargetRanger中,但目前还没有
组织成等级。此外,TargetRanger主要用于发现用于识别的新颖目标
以及移除肿瘤中的癌细胞。因此,将HuBMAP数据作为正常组织背景
这将进一步加强我们提取有用靶点的能力,用于从肿瘤中去除特定细胞,
对整个人体的正常健康细胞和组织的损害最小。我们的目标是让HuBMAP
和ARCHS 4数据更容易访问的研究人员,同时使比较与其他地图集项目。通过
处理HuBMAP数据集并将其整合到GeneRanger和TargetRanger资源中,我们可以识别
如何提高HuBMAP数据的可访问性,以供其他寻求利用其进行分析和添加的人使用
生物信息学工具和数据库的价值。我们相信,这一知识整合工作将提高
HuBMAP、ARCHS 4以及GeneRanger和TargetRanger在研究界的实用性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Avi Ma'ayan其他文献
Avi Ma'ayan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Avi Ma'ayan', 18)}}的其他基金
ARCHS4: Massive Mining of Publicly Available RNA Sequencing Data
ARCHS4:大规模挖掘公开的 RNA 测序数据
- 批准号:
10693339 - 财政年份:2022
- 资助金额:
$ 15万 - 项目类别:
Proteogenomic translator for cancer biomarker discovery towards precision medicine
用于癌症生物标志物发现和精准医学的蛋白质基因组翻译
- 批准号:
10442088 - 财政年份:2022
- 资助金额:
$ 15万 - 项目类别:
ARCHS4: Massive Mining of Publicly Available RNA Sequencing Data
ARCHS4:大规模挖掘公开的 RNA 测序数据
- 批准号:
10527721 - 财政年份:2022
- 资助金额:
$ 15万 - 项目类别:
Proteogenomic translator for cancer biomarker discovery towards precision medicine
用于癌症生物标志物发现和精准医学的蛋白质基因组翻译
- 批准号:
10655588 - 财政年份:2022
- 资助金额:
$ 15万 - 项目类别:
The LINCS DCIC Engagement Plan with the CFDE
LINCS DCIC 与 CFDE 的合作计划
- 批准号:
10837964 - 财政年份:2020
- 资助金额:
$ 15万 - 项目类别:
The LINCS DCIC Engagement Plan with the CFDE
LINCS DCIC 与 CFDE 的合作计划
- 批准号:
10468520 - 财政年份:2020
- 资助金额:
$ 15万 - 项目类别:
The LINCS DCIC Engagement Plan with the CFDE
LINCS DCIC 与 CFDE 的合作计划
- 批准号:
10444350 - 财政年份:2020
- 资助金额:
$ 15万 - 项目类别:
The LINCS DCIC Engagement Plan with the CFDE
LINCS DCIC 与 CFDE 的合作计划
- 批准号:
10682935 - 财政年份:2020
- 资助金额:
$ 15万 - 项目类别:
Knowledge Management Center for Illuminating the Druggable Genome
阐明可药物基因组的知识管理中心
- 批准号:
10560469 - 财政年份:2018
- 资助金额:
$ 15万 - 项目类别:
相似海外基金
Development of antibody drug conjugates as pan-filo antivirals
开发作为泛型抗病毒药物的抗体药物偶联物
- 批准号:
10759731 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Proteasome Inhibitor-Loaded Antibody Drug Conjugates with High Drug Loading For Targeted Treatment of Triple Negative Breast Cancers
负载蛋白酶体抑制剂的高载药量抗体药物偶联物用于三阴性乳腺癌的靶向治疗
- 批准号:
10822628 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Next Generation Bio-Orthogonal Ynamine Reagents for the Preparation of Antibody-Drug Conjugates
用于制备抗体-药物缀合物的下一代生物正交胺试剂
- 批准号:
2889322 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Studentship
Novel antibody-drug conjugates targeting T-cell lymphoma
靶向 T 细胞淋巴瘤的新型抗体-药物偶联物
- 批准号:
10386723 - 财政年份:2022
- 资助金额:
$ 15万 - 项目类别:
Establishment and validation of the methods for the production of antibody-drug conjugates against malignant skin tumors
抗恶性皮肤肿瘤抗体药物偶联物生产方法的建立和验证
- 批准号:
22K16283 - 财政年份:2022
- 资助金额:
$ 15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Targeting breast cancer via site-specific antibody-drug conjugates based on biosynthetically modified enediyne natural products
通过基于生物合成修饰的烯二炔天然产物的位点特异性抗体药物缀合物靶向乳腺癌
- 批准号:
514898299 - 财政年份:2022
- 资助金额:
$ 15万 - 项目类别:
WBP Fellowship
Developing Novel Bispecific Antibody-Drug Conjugates to Treat Leukaemia
开发新型双特异性抗体药物偶联物来治疗白血病
- 批准号:
2600922 - 财政年份:2021
- 资助金额:
$ 15万 - 项目类别:
Studentship
Project 6- Targeting AML using bispecific and antibody drug conjugates
项目 6 - 使用双特异性和抗体药物偶联物靶向 AML
- 批准号:
10615336 - 财政年份:2021
- 资助金额:
$ 15万 - 项目类别:
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
抗体药物偶联物对三阴性乳腺癌的协同靶向治疗
- 批准号:
9886056 - 财政年份:2020
- 资助金额:
$ 15万 - 项目类别:
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
抗体药物偶联物对三阴性乳腺癌的协同靶向治疗
- 批准号:
10322410 - 财政年份:2020
- 资助金额:
$ 15万 - 项目类别: